Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...
The latest announcement is out from Annexon Biosciences ( (ANNX) ).
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...
Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results